Welcome to our dedicated page for Ernexa SEC filings (Ticker: ERNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a pre-clinical biotech filing can feel like reading a foreign language—especially when Eterna Therapeutics packs hundreds of pages with gene-editing jargon, milestone payment tables, and clinical trial risk factors. If you are hunting for cash-runway details or wondering how ERNA accounts for its Factor Bioscience license fees, scrolling through dense 10-Ks isn’t the best use of your time.
Stock Titan’s AI-powered analysis scans every fresh document the moment it hits EDGAR. Whether you need the Eterna Therapeutics quarterly earnings report 10-Q filing to track R&D burn, or want Eterna Therapeutics insider trading Form 4 transactions in real-time, our platform highlights exactly where those numbers—and their context—sit inside the report. Plain-English summaries turn complex sections on clinical trial protocols, goodwill impairment, and going-concern language into short takeaways you can act on.
Still asking, “How do I read Eterna Therapeutics’ 10-K annual report?” or “Where did management discuss ERNA-101’s next milestone?” Use the navigation below to jump straight to:
- 10-K & 10-Q—cash, collaborations, and risk factors explained simply.
- 8-K material events—drug-trial updates decoded within minutes.
- Form 4 insider transactions—see executive stock moves before the market reacts.
- Proxy statements—executive compensation and share-dilution scenarios laid out clearly.
From “understanding Eterna Therapeutics SEC documents with AI” to comparing Eterna Therapeutics executive stock transactions Form 4 across quarters, Stock Titan delivers the insights professionals need—without the biotech word salad.
IAF, LLC reports it currently beneficially owns 315,779 shares of Ernexa Therapeutics Inc. common stock, representing 4.1% of the outstanding class based on 7,670,889 shares reported by the issuer. This Amendment No. 3 updates prior Schedule 13G filings and indicates the reporting person has ceased to own more than 5% of the company, making this an "exit filing." The filing shows all 315,779 shares are held with sole voting and sole dispositive power and confirms the holder does not report ownership on behalf of others or as part of a group.
Ernexa Therapeutics is a preclinical synthetic allogeneic iMSC therapy company developing ERNA-101 (IL-7/IL-15–secreting) for oncology and ERNA-201 for inflammatory disorders. Management expects to complete IND-enabling studies and submit an IND in 2026 with a planned Phase I investigator-sponsored trial in the second half of 2026.
Financially, the company reported $4.3 million in cash and an accumulated deficit of $242.9 million. Net loss was $3.1 million for the quarter and $11.3 million for the six months, which includes a $5.8 million non-cash forward sales contract expense. Ernexa raised approximately $7.2 million gross from a private placement, completed a 1-for-15 reverse stock split and increased authorized common shares to 150 million. Management disclosed substantial doubt aboutgoing concern and stated additional financing will be required. Stockholders' equity was $4.4 million at period end and the company reports compliance with Nasdaq continued listing standards.
Ernexa Therapeutics Inc. (CIK 0000748592) has received SEC clearance for its shelf registration. The company’s Form S-3 registration statement (File No. 333-287954) was declared effective on 18 June 2025 at 4:30 p.m. Eastern Time. A Form S-3 allows eligible issuers to register multiple classes of securities and later access capital markets quickly through takedowns without filing a new registration with each offering.
While the filing itself contains no financial metrics or details on the amount or type of securities that may be offered, effectiveness formally authorises Ernexa to issue securities when market conditions are favourable. Investors should monitor subsequent prospectus supplements for specific terms, such as share counts, pricing, and potential dilution.
FAQ
What is the current stock price of Ernexa (ERNA)?
What is the market cap of Ernexa (ERNA)?
